Citicoline and Alpha-GPC: Choline-Related Cognitive Products
Citicoline and alpha-GPC are choline-related compounds sold for memory. Here is what they are, what trials in patients and healthy adults found, and what the safety questions are.
Content last updated . This page has not been medically reviewed.
What is Citicoline and alpha-GPC good for?
What the body uses it for, and how strong the evidence is. A normal job in the body is not proof that extra supplements add benefit; each card says which.
Choline-containing building blocks for cell membranes
Lab or animal research onlyCiticoline is described as a precursor the body uses to make phosphatidylcholine, a cell-membrane component, and it is a substance the body normally produces.
Supplements: No evidence that supplements add anything beyond normal membrane building when intake of choline is adequate.
Memory in older adults with chronic brain disorders (citicoline)
Preliminary or mixedA 2005 Cochrane review of 14 mostly short trials found no evidence of benefit on attention and some evidence of benefit on memory and behaviour in older people with chronic brain disorders.
Supplements: Evidence is old, short and varied; patient results do not transfer to healthy adults. A 2023 meta-analysis found cognitive scores improved but rated study quality poor.
Memory in healthy older adults with age-associated memory impairment (citicoline)
Preliminary or mixedOne 12-week trial in 100 people aged 50 to 85 reported larger gains than placebo on computerized episodic-memory tests.
Supplements: Single trial; not confirmed by others in sources we read.
Cognition in adult-onset cognitive impairment (alpha-GPC)
Preliminary or mixedA 2023 meta-analysis of seven randomized trials and one cohort study reported better cognition, function and behaviour when alpha-GPC was added to donepezil, and better cognition than placebo or other medicines in one comparison.
Supplements: Limited evidence in patients; no good evidence of memory benefit in healthy older adults was found.
Alpha-GPC versus citicoline in dementia
Preliminary or mixedA 2025 meta-analysis of three trials (358 people) found a clinical rating scale favoured alpha-GPC, while memory and word-fluency tests did not differ.
Supplements: Cannot show that either one works better than no treatment.
Short-term thinking tasks in healthy young men (alpha-GPC)
Preliminary or mixedIn a small crossover trial of 20 men, Stroop scores changed more after alpha-GPC than placebo, with no difference on two other tests.
Supplements: Small and short; results do not transfer to women, older adults or longer use.
Recovery after acute ischemic stroke (citicoline)
Not enough evidenceThe ICTUS trial of 2,298 patients found recovery at 90 days similar to placebo, and was stopped for futility. A 2020 Cochrane review of 10 trials also found little or no difference.
Supplements: No good evidence of benefit for stroke recovery.
Glaucoma (citicoline)
Not enough evidenceA 2023 systematic review of 10 studies found no significant difference in eye pressure or visual field and judged the evidence insufficient to say citicoline slows glaucoma.
Supplements: Insufficient evidence; never a replacement for prescribed eye drops.
Connected topics
Open a group to see how each topic connects and how strong the evidence is.
Health goals (1)
- Memory SupportPreliminary or mixed
One trial in healthy older adults and several in patients reported memory gains on tests; quality is limited and results do not transfer between groups.
Body systems (4)
- Brain & FocusPreliminary or mixed
Sold for memory and focus. Trials are mostly in older people with memory problems and are varied and often low quality; healthy-adult evidence is thin.
- Cardiovascular SystemDocumented risk
A very large Korean study linked prescribed alpha-GPC to more strokes over 10 years. This is an association, not proof of cause.
- Nervous SystemPreliminary or mixed
Choline-containing compounds feed membrane and nerve-messenger pathways, but benefits for the nervous system in healthy people are not shown.
- Heart & CirculationDocumented risk
Stroke is a blood-vessel event; the alpha-GPC stroke association is the reason to ask a clinician first if you have heart or circulation disease.
Body parts (4)
- BrainPreliminary or mixed
The brain is where the compounds are meant to act. Results are mixed and mostly from patients.
- Blood VesselsDocumented risk
Observational link between alpha-GPC prescriptions and stroke (blocked and bleeding types).
- CellsLab or animal research only
Citicoline is described as a precursor of phosphatidylcholine, a cell-membrane component. Animal research suggests membrane effects; human benefit is not shown.
- Nervous SystemLab or animal research only
Choline is used to make the nerve messenger acetylcholine and cell-membrane phospholipids; this is a normal role of choline, not proof that these supplements help.
Functional actions (1)
- Cognitive EnhancementPreliminary or mixed
Marketed as cognitive enhancers. Small or low-quality trials, mostly in patients, give limited and mixed results.
Conditions & symptoms (4)
- Cerebrovascular AccidentDocumented risk
Prescribed alpha-GPC was associated with higher total, ischemic and bleeding-type stroke risk over 10 years in Korean registry data; this does not prove cause.
- DementiaPreliminary or mixed
Alpha-GPC added to donepezil and citicoline alone have been studied in dementia with limited, mixed results; neither replaces diagnosis or treatment.
- Mild Cognitive DisorderPreliminary or mixed
Meta-analyses of citicoline and alpha-GPC report better test scores in mild cognitive impairment, but studies were small or poor quality, so no one should treat this as proven.
- Age-Associated Memory ImpairmentPreliminary or mixed
One 12-week trial in healthy older adults with this kind of memory change reported better episodic-memory scores than placebo; it is a single trial.
Documented risks and interactions (1)
- Higher stroke risk in a large observational study (alpha-GPC). In about 12 million Korean adults aged 50 and over, people prescribed alpha-GPC had more strokes over 10 years, rising with greater use. This shows an association, not that it caused strokes.
What they are, and how they differ from choline
Choline is an essential nutrient found in food; its intake levels and food sources are covered in Choline. Citicoline and alpha-GPC are different compounds that the body can break down to supply choline and related building blocks.A Cochrane review describes CDP-choline as a precursor needed to make phosphatidylcholine, a cell-membrane component, and as a substance the body normally produces; as a drug it can be called citicoline. [2] The same review says it is a frequently prescribed drug for cognitive impairment in several European countries. [2] Choline alphoscerate is described in a 2023 review as a choline-containing phospholipid used as a medicine or nutraceutical, with discrepancies between countries about whether it is approved as a prescription medicine. [4]
US regulatory note (FDA, 2019). In a joint FDA and Federal Trade Commission warning letter to an online seller, the FDA wrote that products including alpha-GPC and CDP-choline capsules were "new drugs" because of the disease claims made for them, such as preventing Alzheimer's disease. [5] That letter concerns one seller's claims in 2019; it is not a ruling on the compounds themselves. The National Institute on Aging advises checking with a doctor before trying any supplement that promises to prevent Alzheimer's. [6]
Official intake levels
Proper evidence not found. In the sources we read, neither compound has an RDA, AI or upper limit, and no deficiency syndrome is described for either. Official figures exist for choline itself; see Choline and the brain.Evidence by use
| Question | What the source found | Strength |
|---|---|---|
| Citicoline in older adults with chronic brain disorders | Cochrane review (2005) of 14 trials, most lasting three months or less: no evidence of benefit on attention, evidence of benefit on memory and behavior, and the drug was well tolerated. The lead reviewer had been involved in some included studies. [2] | Limited, dated |
| Citicoline in mild cognitive impairment, Alzheimer's, post-stroke dementia | Meta-analysis (2023) of six studies: cognitive scores improved, but study quality was poor with significant risk of bias favoring the treatment. [1] | Insufficient (poor-quality studies) |
| Citicoline in healthy older adults with age-associated memory impairment | One 12-week trial in 100 people aged 50 to 85 found greater improvement in episodic memory on computerized tests than placebo. [7] Details are on the citicoline trials page. | Promising but limited (single trial) |
| Alpha-GPC in adult-onset cognitive impairment | Meta-analysis (2023) of seven randomized trials and one cohort study: improvements in cognition, function and behavior when alpha-GPC was added to the dementia medicine donepezil, and better cognition than placebo or other medicines in one comparison. [4] | Limited |
| Alpha-GPC versus citicoline in dementia | Meta-analysis (2025) of three trials, 358 people: a clinical rating scale favored alpha-GPC; memory and word-fluency tests did not differ. It compares the two, not either against placebo. [8] | Limited |
| Citicoline or phosphatidylserine in mental disorders | Systematic review (2026) of 11 studies: heterogeneous, inconsistent results; evidence does not support them as effective cognitive enhancers there. [9] | Insufficient |
Results from patients do not transfer to healthy people, or the reverse. Short lab tasks are not everyday performance.
Labels and quality
Check which compound is named (the names are easily confused), whether the label lists both, and whether the product is a blend. Disease claims are a warning sign. See reading supplement labels and quality testing and certifications.Frequently asked questions
Is citicoline the same as choline?
No. Choline is an essential nutrient; citicoline is a related compound the body breaks down. See Choline. [2]
Does citicoline improve memory?
In older patients, a Cochrane review found evidence of benefit on memory in short trials. [2] A 2023 meta-analysis found improvements but rated study quality poor. [1]
Is alpha-GPC safe?
A large Korean cohort study linked alpha-GPC prescription to higher stroke risk in a dose-response pattern; that does not prove cause. [3]
Is alpha-GPC better than citicoline?
One 2025 meta-analysis of three dementia trials favored alpha-GPC on one rating scale and found no difference on memory tests. [8] See citicoline vs alpha-GPC.
Can either one prevent or treat dementia?
No supplement has been proven to prevent Alzheimer's disease. [6]
More details: evidence, limits and cautions
The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.
How to read the evidence labels
Labels used on this page: established nutritional role, promising but limited, mixed, insufficient evidence and marketing claim. They are explained in What are nootropics?.
Safety, interactions and who should ask first
- Alpha-GPC and stroke. A study of about 12 million Koreans aged 50 and older found higher stroke risk among people prescribed alpha-GPC, with risk rising as intake increased. [3] Read the alpha-GPC page for limits of that design.
- Citicoline tolerability. The trials in the Cochrane reviews described it as well tolerated, but stroke trials reported harms poorly and a 2020 Cochrane review said its safety profile remains unknown. [2][10]
- Medicines. We did not find a source we could read on interactions. Ask a pharmacist, especially about blood thinners, dementia medicines or other prescriptions; see how interactions work.
- Pregnancy, breastfeeding and children: Proper evidence not found in the sources we read; see pregnancy and breastfeeding and children and teens.
- Kidney, liver, older adults, surgery: safety data were not described in the sources we read. Tell your surgical team about any supplement (supplements before surgery) and see older adults.
When to get help
References
- Bonvicini M et al. Nutrients 2023. Is Citicoline Effective in Preventing and Slowing Down Dementia? A Systematic Review and a Meta-Analysis. Read 2026-10-22.
- Fioravanti M, Yanagi M. Cochrane Database Syst Rev 2005. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Read 2026-10-22.
- Lee G et al. JAMA Netw Open 2021. Association of L-α Glycerylphosphorylcholine With Subsequent Stroke Risk After 10 Years. Read 2026-10-23.
- Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis. J Alzheimers Dis 2023. PubMed record. Read 2026-10-23.
- US Food and Drug Administration (with the Federal Trade Commission), Warning letter to an online seller of nootropic products, 565425 (February 5, 2019). Read 2026-10-23.
- National Institute on Aging, Preventing Alzheimer's Disease: What Do We Know?. Read 2026-10-23.
- Nakazaki E et al. J Nutr 2021. Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Read 2026-10-23.
- Sagaro GG, Amenta F. Front Neurol 2025. Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis. Read 2026-10-23.
- Kucuksahin NG et al. Hum Psychopharmacol 2026. The Impact of Citicoline/Phosphatidylserine Supplementation on Cognitive Performance and Executive Functions in Mental Disorders: A Systematic Review of Controlled Trials. Read 2026-10-23.
- Martí-Carvajal AJ et al. Cochrane Database Syst Rev 2020. Citicoline for treating people with acute ischemic stroke. Read 2026-10-23.